Coeptis Therapeutics (COEP) Competitors $13.43 -0.18 (-1.32%) Closing price 04:00 PM EasternExtended Trading$13.36 -0.06 (-0.48%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. ACOG, MEIP, LXEO, KRRO, CTMX, BHST, MOLN, CLLS, THTX, and ENTAShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Alpha Cognition (ACOG), MEI Pharma (MEIP), Lexeo Therapeutics (LXEO), Korro Bio (KRRO), CytomX Therapeutics (CTMX), BioHarvest Sciences (BHST), Molecular Partners (MOLN), Cellectis (CLLS), Theratechnologies (THTX), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Alpha Cognition MEI Pharma Lexeo Therapeutics Korro Bio CytomX Therapeutics BioHarvest Sciences Molecular Partners Cellectis Theratechnologies Enanta Pharmaceuticals Coeptis Therapeutics (NASDAQ:COEP) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Do insiders & institutionals hold more shares of COEP or ACOG? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 14.0% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is COEP or ACOG more profitable? Alpha Cognition's return on equity of -80.16% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -201.73% -108.46% Alpha Cognition N/A -80.16%-60.95% Do analysts recommend COEP or ACOG? Alpha Cognition has a consensus target price of $20.00, suggesting a potential upside of 142.13%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer COEP or ACOG? In the previous week, Alpha Cognition had 10 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 10 mentions for Alpha Cognition and 0 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.68 beat Alpha Cognition's score of -0.08 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Positive Alpha Cognition Neutral Which has more volatility & risk, COEP or ACOG? Coeptis Therapeutics has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Which has better valuation & earnings, COEP or ACOG? Alpha Cognition is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.32Alpha CognitionN/AN/A-$14.64M-$1.60-5.16 SummaryAlpha Cognition beats Coeptis Therapeutics on 8 of the 13 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.14M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-2.3220.4030.4525.16Price / SalesN/A238.54392.5887.64Price / CashN/A42.3737.0358.50Price / Book6.687.918.956.21Net Income-$10.88M-$54.72M$3.26B$265.38M7 Day Performance16.99%1.63%1.06%-1.13%1 Month Performance25.51%5.86%4.31%-0.71%1 Year Performance216.75%8.70%28.40%18.89% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.568 of 5 stars$13.43-1.3%N/A+217.0%$47.14MN/A-2.322News CoverageEarnings ReportShort Interest ↑ACOGAlpha Cognition1.6081 of 5 stars$9.70-2.9%$20.00+106.2%N/A$155.39MN/A-8.08N/AEarnings ReportInsider TradeMEIPMEI Pharma1.7342 of 5 stars$4.79-0.8%N/A+47.6%$155.05M$65.30M-1.01100LXEOLexeo Therapeutics2.3599 of 5 stars$4.67+5.2%$17.17+267.6%-60.6%$155.04M$650K-1.4258News CoverageEarnings ReportAnalyst RevisionKRROKorro Bio1.3309 of 5 stars$15.99+6.2%$102.43+540.6%-54.4%$150.15M$2.27M-1.6970Analyst RevisionGap DownHigh Trading VolumeCTMXCytomX Therapeutics4.0309 of 5 stars$1.86-19.5%$5.75+209.1%+58.9%$149.95M$138.10M3.32170High Trading VolumeBHSTBioHarvest SciencesN/A$9.11+3.3%$13.67+50.0%N/A$149.59M$25.19M-18.22N/AGap UpMOLNMolecular Partners2.398 of 5 stars$3.69+6.3%$12.00+225.2%-43.3%$149.00M$5.65M-1.92180Upcoming EarningsGap UpCLLSCellectis3.3286 of 5 stars$2.66+0.4%$4.00+50.4%+22.6%$147.84M$49.22M-3.24290Positive NewsShort Interest ↓Gap DownTHTXTheratechnologiesN/A$3.21+0.3%N/A+133.1%$147.60M$85.87M-16.89140News CoverageShort Interest ↓ENTAEnanta Pharmaceuticals3.6101 of 5 stars$6.86+5.7%$21.67+215.8%-29.4%$146.67M$67.64M-1.51160 Related Companies and Tools Related Companies Alpha Cognition Alternatives MEI Pharma Alternatives Lexeo Therapeutics Alternatives Korro Bio Alternatives CytomX Therapeutics Alternatives BioHarvest Sciences Alternatives Molecular Partners Alternatives Cellectis Alternatives Theratechnologies Alternatives Enanta Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access